新标准《水质石油类和动植物油的测定红外分光光度法》(HJ 637-2018),采用四氯乙烯为萃取剂,且对其质量要求较高、用量较大,由此产生大量含油四氯乙烯废液。本文采用减压蒸馏法,在较佳回收条件(系统压强为2.95~4.09 k Pa、温度为90℃、...新标准《水质石油类和动植物油的测定红外分光光度法》(HJ 637-2018),采用四氯乙烯为萃取剂,且对其质量要求较高、用量较大,由此产生大量含油四氯乙烯废液。本文采用减压蒸馏法,在较佳回收条件(系统压强为2.95~4.09 k Pa、温度为90℃、转速为120~300r·min^(-1))下,四氯乙烯回收率大于94%,回收速率大于4.6g·min^(-1)。红外测油仪测定回收的四氯乙烯在3030、2960、2930cm^(-1)处吸光度分别为小于0、0.008和0.022,质量达标。用回收的四氯乙烯进行验证实验,相对误差小于2%,回收的四氯乙烯可循环再利用。展开更多
目的总结华东地区大动脉炎(East China Takayasu’s Arteritis,ECTA)队列大动脉炎(Takayasu’s arteritis,TAK)患者的心脏受累特征。方法纳入2009年1月至2019年12月复旦大学附属中山医院ECTA队列TAK患者,所有患者均符合1990年美国风湿...目的总结华东地区大动脉炎(East China Takayasu’s Arteritis,ECTA)队列大动脉炎(Takayasu’s arteritis,TAK)患者的心脏受累特征。方法纳入2009年1月至2019年12月复旦大学附属中山医院ECTA队列TAK患者,所有患者均符合1990年美国风湿病学会TAK分类标准,排除具有病毒性心肌炎、风湿性心脏病或先天性心脏病病史的TAK患者。将上述患者分为心脏受累组和无心脏受累组,分析心脏受累特点并比较两组临床资料。结果共纳入TAK患者390例,其中心脏受累组186例(47.7%)。TAK患者中心脏瓣膜病155例(39.7%),冠脉受累52例(13.3%),肺动脉高压51例(13.1%),高血压性心脏病17例(4.4%),心肌病7例(1.8%)。心脏受累组男女比例为1∶5.6,初发中位年龄为32.6(23.3~45.4)岁,中位病程为30.0(6.4~108.5)个月。心脏受累组患者更易出现胸闷、胸痛、气促等表现(P<0.05),氨基末端脑钠肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)水平也高于无心脏受累组(P<0.001)。Ⅱb型TAK患者更容易出现心脏受累。结论TAK心脏受累并不少见,ECTA队列中心脏受累的患者约47.7%,以瓣膜病、冠脉受累多见,建议规律随访以便早期发现心脏受累的高危患者。展开更多
目的明确大动脉炎(Takayasu s arteritis,TAK)患者的心电图特征及其与临床资料、心脏功能和结构改变的相关性。方法回顾性分析复旦大学附属中山医院风湿免疫科2012年1月至2019年12月首次住院并完成心电图检查的TAK患者的临床资料。结果...目的明确大动脉炎(Takayasu s arteritis,TAK)患者的心电图特征及其与临床资料、心脏功能和结构改变的相关性。方法回顾性分析复旦大学附属中山医院风湿免疫科2012年1月至2019年12月首次住院并完成心电图检查的TAK患者的临床资料。结果共纳入343例TAK患者,其中女性283例(82.5%),男女比例为1∶4.7;初发中位年龄为28.8(21.3~40.2)岁,中位病程为20.8(3.5~67.4)月。170例(49.6%)有异常心电图表现,以左心室肥厚(25.4%)、ST-T段(28.0%)及T波改变(15.5%)为主。异常心电图组患者中Ⅴ型大动脉炎最常见(58.8%),高血压占43.5%,57.6%有胸闷、气促、心悸等症状,初发年龄较正常组晚(P<0.001),肿瘤坏死因子-α(P=0.016)及氨基末端利钠肽前体(P<0.001)明显高于正常组,而血小板计数显著降低(P=0.008)。起病年龄超过38岁、Ⅴ型大动脉炎、肿瘤坏死因子-α≥8.1 pg mL与TAK患者心电图异常显著相关。异常心电图伴TAK严重病变中女性多见(P=0.044),病程更长(P<0.001),纽约心功能分极Ⅲ-Ⅳ比例较高(P<0.001),血红蛋白水平较低(P=0.025)。结论半数左右TAK患者心电图异常,心电图检查有助于早期发现心脏损害的TAK患者。展开更多
Huang-Qin Decoction(HQD)is a classic prescription for diarrhea in Chinese medicine treatment.Recent studies have demonstrated that HQD and its modified formulation PHY906 could ameliorate irinotecan(CPT-11)induced gas...Huang-Qin Decoction(HQD)is a classic prescription for diarrhea in Chinese medicine treatment.Recent studies have demonstrated that HQD and its modified formulation PHY906 could ameliorate irinotecan(CPT-11)induced gastrointestinal(GI)toxicity and enhance its anticancer therapeutic efficacy.Nevertheless,which constituents in HQD are effective is still unclear so far.The study aims to screen out the key bioactive components combination from HQD that could enhance the anticancer effect of CPT-11.First,the potential bioactive constituents were obtained through system pharmacology strategy.Then the bioactivity of each constituent was investigated synthetically from the aspects of NCM460 cell migration,TNF-αrelease of THP-1-derived macrophage and MTT assay in HCT116 cell.The contribution of each constituent in HQD was evaluated using the bioactive index Ei,which taken the content and bioactivity into comprehensive consideration.And then,the most contributing constituents were selected out to form a keycomponent combination.At last,the bioefficacy of the key-component combination was validated in vitro and in vivo.As a result,a key-component combination(HB4)consisting of four compounds baicalin,baicalein,glycyrrhizic acid and wogonin was screened out.In vitro assessment indicated that HB4 could enhance the effect of CPT-11 on inhibiting cell proliferation and inducing apoptosis in HCT116.Furthermore,the in vivo study confirmed that HB4 and HQD have similar pharmacological activity and could both enhance the antitumor effect of CPT-11 in HCT116 xenograft model.Meanwhile,HB4 could also reduce the CPT-11 induced GI toxicity.展开更多
文摘新标准《水质石油类和动植物油的测定红外分光光度法》(HJ 637-2018),采用四氯乙烯为萃取剂,且对其质量要求较高、用量较大,由此产生大量含油四氯乙烯废液。本文采用减压蒸馏法,在较佳回收条件(系统压强为2.95~4.09 k Pa、温度为90℃、转速为120~300r·min^(-1))下,四氯乙烯回收率大于94%,回收速率大于4.6g·min^(-1)。红外测油仪测定回收的四氯乙烯在3030、2960、2930cm^(-1)处吸光度分别为小于0、0.008和0.022,质量达标。用回收的四氯乙烯进行验证实验,相对误差小于2%,回收的四氯乙烯可循环再利用。
文摘目的总结华东地区大动脉炎(East China Takayasu’s Arteritis,ECTA)队列大动脉炎(Takayasu’s arteritis,TAK)患者的心脏受累特征。方法纳入2009年1月至2019年12月复旦大学附属中山医院ECTA队列TAK患者,所有患者均符合1990年美国风湿病学会TAK分类标准,排除具有病毒性心肌炎、风湿性心脏病或先天性心脏病病史的TAK患者。将上述患者分为心脏受累组和无心脏受累组,分析心脏受累特点并比较两组临床资料。结果共纳入TAK患者390例,其中心脏受累组186例(47.7%)。TAK患者中心脏瓣膜病155例(39.7%),冠脉受累52例(13.3%),肺动脉高压51例(13.1%),高血压性心脏病17例(4.4%),心肌病7例(1.8%)。心脏受累组男女比例为1∶5.6,初发中位年龄为32.6(23.3~45.4)岁,中位病程为30.0(6.4~108.5)个月。心脏受累组患者更易出现胸闷、胸痛、气促等表现(P<0.05),氨基末端脑钠肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)水平也高于无心脏受累组(P<0.001)。Ⅱb型TAK患者更容易出现心脏受累。结论TAK心脏受累并不少见,ECTA队列中心脏受累的患者约47.7%,以瓣膜病、冠脉受累多见,建议规律随访以便早期发现心脏受累的高危患者。
文摘目的明确大动脉炎(Takayasu s arteritis,TAK)患者的心电图特征及其与临床资料、心脏功能和结构改变的相关性。方法回顾性分析复旦大学附属中山医院风湿免疫科2012年1月至2019年12月首次住院并完成心电图检查的TAK患者的临床资料。结果共纳入343例TAK患者,其中女性283例(82.5%),男女比例为1∶4.7;初发中位年龄为28.8(21.3~40.2)岁,中位病程为20.8(3.5~67.4)月。170例(49.6%)有异常心电图表现,以左心室肥厚(25.4%)、ST-T段(28.0%)及T波改变(15.5%)为主。异常心电图组患者中Ⅴ型大动脉炎最常见(58.8%),高血压占43.5%,57.6%有胸闷、气促、心悸等症状,初发年龄较正常组晚(P<0.001),肿瘤坏死因子-α(P=0.016)及氨基末端利钠肽前体(P<0.001)明显高于正常组,而血小板计数显著降低(P=0.008)。起病年龄超过38岁、Ⅴ型大动脉炎、肿瘤坏死因子-α≥8.1 pg mL与TAK患者心电图异常显著相关。异常心电图伴TAK严重病变中女性多见(P=0.044),病程更长(P<0.001),纽约心功能分极Ⅲ-Ⅳ比例较高(P<0.001),血红蛋白水平较低(P=0.025)。结论半数左右TAK患者心电图异常,心电图检查有助于早期发现心脏损害的TAK患者。
基金the NSFC(Nos.81773861,81302733)Jiangsu Provincial National Science Foundation for Distinguished Young Scholars(No.BK20180027)+3 种基金National Science and Technology Major Project(2017ZX09101001)Double First-Class University projectthe Program for Jiangsu Province Innovative Research Teama project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD)gsu Higher Education Institutions(PAPD)。
文摘Huang-Qin Decoction(HQD)is a classic prescription for diarrhea in Chinese medicine treatment.Recent studies have demonstrated that HQD and its modified formulation PHY906 could ameliorate irinotecan(CPT-11)induced gastrointestinal(GI)toxicity and enhance its anticancer therapeutic efficacy.Nevertheless,which constituents in HQD are effective is still unclear so far.The study aims to screen out the key bioactive components combination from HQD that could enhance the anticancer effect of CPT-11.First,the potential bioactive constituents were obtained through system pharmacology strategy.Then the bioactivity of each constituent was investigated synthetically from the aspects of NCM460 cell migration,TNF-αrelease of THP-1-derived macrophage and MTT assay in HCT116 cell.The contribution of each constituent in HQD was evaluated using the bioactive index Ei,which taken the content and bioactivity into comprehensive consideration.And then,the most contributing constituents were selected out to form a keycomponent combination.At last,the bioefficacy of the key-component combination was validated in vitro and in vivo.As a result,a key-component combination(HB4)consisting of four compounds baicalin,baicalein,glycyrrhizic acid and wogonin was screened out.In vitro assessment indicated that HB4 could enhance the effect of CPT-11 on inhibiting cell proliferation and inducing apoptosis in HCT116.Furthermore,the in vivo study confirmed that HB4 and HQD have similar pharmacological activity and could both enhance the antitumor effect of CPT-11 in HCT116 xenograft model.Meanwhile,HB4 could also reduce the CPT-11 induced GI toxicity.
